Loading market dashboard
VictoryShares US Discovery Enhanced Volatility Wtd ETF
CSFFinancial ServicesNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending shares of the Nasdaq-listed company up 8.7% to $5.89 Thursday. CNSide Diagnostics' Houston-based clinical laboratory underwent a rigorous on-site inspection evaluating clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, and overall laboratory management.
New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization tracking New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization tracking
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Highmark joins a growing list of national and regional payers, including United Healthcare and Humana, that provide coverage for CNSide.
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with high baseline CSF glucosylsphingosine
